Michael Gelband’s Mesa Laboratories MLAB Stock Holding History

Michael Gelband’s Portfolio MLAB Stock Details MLAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,937	Closed	-$545K	–	1891
2025 Q4	$545K	Buy	+6,937	New	+$528K	﹤0.01%	1167
2025 Q1	–	Sell	-9,692	Closed	-$1.28M	–	1795
2024 Q4	$1.28M	Buy	9,692 +7,167	+284%	+$880K	0.01%	867
2024 Q3	$328K	Buy	+2,525	New	+$297K	﹤0.01%	1332
2024 Q1	–	Sell	-2,200	Closed	-$230K	–	1788
2023 Q4	$230K	Buy	+2,200	New	+$214K	﹤0.01%	1246
2022 Q4	–	Sell	-1,614	Closed	-$227K	–	1935
2022 Q3	$227K	Sell	1,614 -195	-11%	-$35.6K	﹤0.01%	1605
2022 Q2	$369K	Buy	+1,809	New	+$396K	﹤0.01%	1458
2021 Q2	–	Sell	-1,197	Closed	-$291K	–	2632
2021 Q1	$291K	Buy	+1,197	New	+$329K	﹤0.01%	1698
2020 Q3	–	Sell	-5,014	Closed	-$1.09M	–	2047
2020 Q2	$1.09M	Buy	+5,014	New	+$1.16M	0.03%	704

Other funds holding MLAB

LPP

Long Path Partners Stamford, Connecticut $235M AUM 22.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RIM

Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Diamond Hill Capital Management Columbus, Ohio $12.5B AUM 7.49% 1-Year Est. Return

Michael Gelband's MLAB Position: Q1 2026 in Review

Michael Gelband sold out of Mesa Laboratories (MLAB) in Q1 2026, closing a stake of 6,937 shares — an estimated $545K sold.

Michael Gelband first reported a position in MLAB in Q2 2020 and held it in 8 quarters. The position peaked at $1.28M in Q4 2024. 161 funds tracked by Wall St. Rank hold MLAB as of Q1 2026.

Michael Gelband reported no remaining Mesa Laboratories position as of Q1 2026 after selling out during the quarter.
Michael Gelband sold 6,937 Mesa Laboratories shares in Q1 2026, an estimated $545K.
Michael Gelband first reported a position in Mesa Laboratories in Q2 2020 and held it in 8 quarters.
Michael Gelband's Mesa Laboratories position peaked at $1.28M in Q4 2024.
161 funds tracked by Wall St. Rank held Mesa Laboratories as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.